GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pressure BioSciences Inc (OTCPK:PBIO) » Definitions » Operating Income

Pressure BioSciences (Pressure BioSciences) Operating Income : $-7.56 Mil (TTM As of Sep. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Pressure BioSciences Operating Income?

Pressure BioSciences's Operating Income for the three months ended in Sep. 2023 was $-1.29 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 was $-7.56 Mil.

Warning Sign:

Pressure BioSciences Inc has never been profitable in the past 3 years. It lost money every year.

Operating Margin % is calculated as Operating Income divided by its Revenue. Pressure BioSciences's Operating Income for the three months ended in Sep. 2023 was $-1.29 Mil. Pressure BioSciences's Revenue for the three months ended in Sep. 2023 was $0.41 Mil. Therefore, Pressure BioSciences's Operating Margin % for the quarter that ended in Sep. 2023 was -313.08%.

Warning Sign:

Pressure BioSciences Inc operating margin has been in a 5-year decline. The average rate of decline per year is -6.3%.

Pressure BioSciences's 5-Year average Growth Rate for Operating Margin % was -6.30% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pressure BioSciences's annualized ROC % for the quarter that ended in Sep. 2023 was -24.31%. Pressure BioSciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -1,986.15%.


Pressure BioSciences Operating Income Historical Data

The historical data trend for Pressure BioSciences's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pressure BioSciences Operating Income Chart

Pressure BioSciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.48 -5.81 -4.59 -4.19 -4.90

Pressure BioSciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.36 -1.55 -3.64 -1.08 -1.29

Pressure BioSciences Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pressure BioSciences  (OTCPK:PBIO) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pressure BioSciences's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

ROC % (Q: Sep. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Sep. 2023 ))/ count )
=-5.172 * ( 1 - 0% )/( (20.379 + 22.177)/ 2 )
=-5.172/21.278
=-24.31 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Pressure BioSciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Sep. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-5.164/( ( (0.269 + max(-6.356, 0)) + (0.251 + max(-7.975, 0)) )/ 2 )
=-5.164/( ( 0.269 + 0.251 )/ 2 )
=-5.164/0.26
=-1,986.15 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.189 + 0.554 + 0.281) - (6.789 + 0.302 + 0.289)
=-6.356

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.329 + 0.467 + 0.22) - (8.362 + 0.253 + 0.376)
=-7.975

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Pressure BioSciences's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-1.293/0.413
=-313.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Pressure BioSciences Operating Income Related Terms

Thank you for viewing the detailed overview of Pressure BioSciences's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Pressure BioSciences (Pressure BioSciences) Business Description

Traded in Other Exchanges
N/A
Address
14 Norfolk Avenue, South Easton, MA, USA, 02375
Pressure BioSciences Inc is engaged in the healthcare division. The firm is a leader in the development & sale of innovative, enabling, pressure-based platform solutions for the worldwide life sciences industry. The company has developed and patented a technology platform that can control the sample preparation process. This process, called pressure cycling technology (PCT), uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels. The company is also the distributor of the Constant Systems (CS) cell disruption equipment, parts, and consumables. Its products include Barocyclers, External Pressure Calibration Device Kits, MicroTubes, HUB High-Pressure Generators, and Accessories.
Executives
Daniel Joseph Shea officer: Senior Vice President & CFO 2 MINUTEMAN ROAD, MEDFIELD MA 02052
Bradford Addison Young officer: Chief Commercial Officer 513 LITTLE JOHN HILL, ANNAPOLIS MD 21405
Richard T Schumacher director, officer: Chief Executive Officer 375 WEST STREET, WEST BRIDGEWATER MA 02379
Nathan Lawrence other: VP Sales and Marketing 321 MANLEY STREET, WEST BRIDGEWATER MA 02379
Richard Thomley officer: Chief Financial Officer C/O PRESSURE BIOSCIENCES, INC., 14 NORFOLK AVE., SOUTH EASTON MA 02375
Kevin Pollack director 150 RAINVILLE ROAD, TARPON SPRINGS FL 34689
Michael S Urdea director 100 BUNCE MEADOWS DRIVE, ALAMO CA 94507
Alexander V Lazarev officer: VP of REsearch and Development 18 WINCHESTER DRIVE, LEXINGTON MA 02420
Edmund Y Ting officer: Senior VP of Engineering 23642 123RD PLACE SOUTHEAST, KENT WA 48031
Vito J Mangiardi director 12 POINT GALLINAS ROAD, SAN RAFAEL CA 94903
Jeffrey N Peterson director 1031 SHORELINE DRIVE, SAN MATEO CA 94404
Mir Conrad F officer: CFO 19 BRIER LANE, CLIFTON NJ 07012
Clayton A Struve 10 percent owner 175 W JACKSON BLVD, SUITE 440, CHICAGO IL 60604
Css Llc/il other: (a) 175 WEST JACKSON BLVD, SUITE 440, CHICAGO IL 60604
R Wayne Fritzsche director 835 GREENS PARKWAY, SUITE 150, HOUSTON TX 77067

Pressure BioSciences (Pressure BioSciences) Headlines

From GuruFocus